Engene to participate in upcoming investor conferences

Boston & montreal--(business wire)--engene holdings inc. (nasdaq: engn, “engene” or the “company”), a clinical-stage genetic medicines company whose non-viral lead program detalimogene voraplasmid (also known as detalimogene, and previously eg-70), is in an ongoing pivotal study in patients with high-risk, bacillus calmette-guÉrin (bcg)-unresponsive, non-muscle invasive bladder cancer (nmibc) with carcinoma in situ (cis), today announced that the company will participate in several upcoming inv.
ENGN Ratings Summary
ENGN Quant Ranking